SCHEMBL16992123

SCHEMBL16992123

CCOC(=O)N1CCC2(CC(N3CCC4(CC3)OCCO4)C2)C1

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CHRM4 P08173 2/20 0.50
POLB P06746 1/20 0.47
CHRM2 P08172 1/20 0.46
ALDH1A1 P00352 6/20 0.45
CYP3A4 P08684 2/20 0.45
CYP2C19 P33261 2/20 0.45
CYP2C9 P11712 1/20 0.45
KMT2A Q03164 2/20 0.41
MAPK1 P28482 2/20 0.40
LMNA P02545 1/20 0.40
TSHR P16473 3/20 0.38
TP53 P04637 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
CHRM1 P11229 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
HRH3 Q9Y5N1 1/20 0.37
KDM4E B2RXH2 1/20 0.36
HSD17B10 Q99714 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27373378 1.00 CHRM4 (0.50) CHRM4POLBCHRM2ALDH1A1CYP3A4
SCHEMBL27373106 0.84 SCD5 (0.42) CHRM4POLBKMT2ASMN1; SMN2HRH3
SCHEMBL20310714 0.83 CHRM4 (0.54) CHRM4POLBCHRM2ALDH1A1CYP2C9
SCHEMBL20310706 0.82 CHRM4 (0.57) CHRM4CHRM2ALDH1A1MAPK1TP53
SCHEMBL16992573 0.82 CHRM4 (0.54) CHRM4CHRM2ALDH1A1MAPK1TSHR
SCHEMBL27372454 0.82 ALDH1A1 (0.39) ALDH1A1CYP2C19KMT2AMAPK1LMNA
SCHEMBL17020250 0.81 CHRM4 (0.56) CHRM4POLBCHRM2ALDH1A1CYP3A4
SCHEMBL15618604 0.81 CHRM4 (0.50) CHRM4POLBCHRM2ALDH1A1KMT2A
SCHEMBL20310664 0.80 CHRM4 (0.57) CHRM4POLBCHRM2ALDH1A1KMT2A
SCHEMBL17001770 0.80 CHRM4 (0.54) CHRM4POLBCHRM2ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3822262-B1 MUSCARINIC AGONISTS HEPTARES THERAPEUTICS LTD (GB) 2024-03-27 EP disclosed
WO-2024028458-A2 MUSCARINIC RECEPTOR AGONISTS HEPTARES THERAPEUTICS LIMITED (GB) 2024-02-08 WO disclosed
US-11091456-B2 Muscarinic agonists HEPTARES THERAPEUTICS LIMITED (GB) 2021-08-17 US disclosed
US-11091456-B2 Muscarinic agonists HEPTARES THERAPEUTICS LIMITED (GB) 2021-08-17 US disclosed
EP-3822262-A1 MUSCARINIC AGONISTS Heptares Therapeutics Limited (GB) 2021-05-19 EP disclosed
EP-3822262-A1 MUSCARINIC AGONISTS Heptares Therapeutics Limited (GB) 2021-05-19 EP disclosed
US-10961225-B2 Bicyclic AZA compounds as muscarinic M1 receptor and/or M4 receptor HEPTARES THERAPEUTICS LIMITED (GB) 2021-03-30 US disclosed
EP-3331869-B1 MUSCARINIC AGONISTS HEPTARES THERAPEUTICS LTD (GB) 2020-12-23 EP disclosed
EP-3331869-B1 MUSCARINIC AGONISTS HEPTARES THERAPEUTICS LTD (GB) 2020-12-23 EP disclosed
US-20200325118-A1 BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR NXERA PHARMA UK LIMITED (GB) 2020-10-15 US disclosed
US-9670183-B2 Bicyclic AZA compounds as muscarinic M1 receptor and/or M4 receptor agonists HEPTARES THERAPEUTICS LIMITED (GB) 2017-06-06 US disclosed
US-20170037025-A1 Muscarinic Agonists NXERA PHARMA UK LIMITED (GB) 2017-02-09 US disclosed
US-20170037025-A1 Muscarinic Agonists NXERA PHARMA UK LIMITED (GB) 2017-02-09 US disclosed
US-20170037025-A1 Muscarinic Agonists NXERA PHARMA UK LIMITED (GB) 2017-02-09 US disclosed
WO-2017021730-A1 MUSCARINIC AGONISTS HEPTARES THERAPEUTICS LIMITED (GB) 2017-02-09 WO disclosed
WO-2017021730-A1 MUSCARINIC AGONISTS HEPTARES THERAPEUTICS LIMITED (GB) 2017-02-09 WO disclosed
US-20170015650-A1 BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR AGONISTS NXERA PHARMA UK LIMITED (GB) 2017-01-19 US disclosed
EP-3102568-A1 BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR AGONISTS Heptares Therapeutics Limited (GB) 2016-12-14 EP disclosed
WO-2015118342-A1 BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AGONISTS. HEPTARES THERAPEUTICS LIMITED (GB) 2015-08-13 WO disclosed
WO-2015118342-A1 BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AGONISTS. HEPTARES THERAPEUTICS LIMITED (GB) 2015-08-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200325118-A1 BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR CHRM1, CHRM2, CHRM4 CHRM4 3/4885POLB 2609/4885CHRM2 2/4885
US-11091456-B2 Muscarinic agonists CHRM1, CHRM2, CHRM3 CHRM4 4/4885POLB 3750/4885CHRM2 2/4885
US-20170015650-A1 BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR AGONISTS CHRM1, CHRM2, CHRM4 CHRM4 3/4885POLB 2571/4885CHRM2 2/4885
US-10961225-B2 Bicyclic AZA compounds as muscarinic M1 receptor and/or M4 receptor CHRM1, CHRM2, CHRM4 CHRM4 3/4885POLB 2609/4885CHRM2 2/4885
US-20170037025-A1 Muscarinic Agonists CHRM1, CHRM2, CHRM3 CHRM4 4/4885POLB 3750/4885CHRM2 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.